MALIGNANT MELANOMAS

BRAF CODON 600 VARIANT TESTING IN MALIGNANT MELANOMAS TO PREDICT RESPONSE TO BRAF KINASE INHIBITORS

Approximately 40 to 60% of cutaneous melanomas carry activating variants in BRAF that lead to the constitutive activation of downstream signaling through the MAPK pathway. Approximately 90% of these variants result in the substitution of glutamic acid for valine at codon 600 (BRAF p.Val600Glu).  Patients with this variant have been shown to respond to BRAF kinase inhibitors (Chapman et al 2011 NEJM 30:2507-2516).

Reporting time: 10 working days from sample receipt.

Laboratory contact: Christopher Bowles 01392 408249 (Christopher.Bowles@nhs.net)

Histopathology contact: Dr Chris Mason 01392 402942 (Chris.mason2@nhs.net)